Department of Cardiology, No.9 People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, No.280, Mohe Road, Baoshan District, 201900 Shanghai, China, 201900 Shanghai, China.
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory of Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cardiol J. 2021;28(1):118-128. doi: 10.5603/CJ.a2019.0051. Epub 2019 May 20.
Reperfusion therapy is known to improve prognosis and limit myocardial damage after myocardial infarction (MI). The administration of antiplatelet drugs prior to percutaneous coronary intervention also proves beneficial to patients with acute MI (AMI). However, a good number of AMI patients do not receive reperfusion therapy, and it is not clear if they would benefit from antiplatelet pre-treatment.
Experimental C57BL/6 mice were randomly allocated to five groups: the sham group, control, post-treatment, pre-treatment, and pre- and post-treatment groups. Acetylsalicylic acid (15 mg/kg), clopidogrel (11 mg/kg), ticagrelor (27 mg/kg), and prasugrel (1.5 mg/kg) were intragastrically administered in the treatment groups. On day 7 post MI, cardiac function and cardiac fibrosis were evaluated using echocardiography and Masson's trichrome staining, respectively. Histopathological examinations were performed on tissue sections to grade inflammatory cell infiltration. Platelet inhibition was monitored by measuring thrombin-induced platelet aggregation.
Left ventricular ejection fraction and fractional shortening improved significantly (p < 0.01) in the pre-treatment groups when compared to the post-treatment and control groups. A significant (p < 0.01) decrease in cardiac fibrosis was observed in the pre-treatment group, compared with the posttreatment and control groups. Inflammatory cell infiltration significantly decreased in the pre-treatment group compared with the control group (p < 0.05). Thrombin-induced platelet aggregation was significantly inhibited by antiplatelet drugs, but increased with the exposure to H2O2.
In the absence of reperfusion therapy, pre-treatment with antiplatelet drugs successfully improved cardiac function, reduced cardiac fibrosis and inflammatory cell infiltration, and inhibited oxidative stress-induced platelet aggregation after MI in the mouse model.
再灌注治疗可改善心肌梗死(MI)后的预后并限制心肌损伤。经皮冠状动脉介入治疗前给予抗血小板药物也对急性 MI(AMI)患者有益。然而,许多 AMI 患者未接受再灌注治疗,目前尚不清楚他们是否会受益于抗血小板预处理。
实验 C57BL/6 小鼠随机分为五组:假手术组、对照组、后处理组、预处理组和预处理后处理组。治疗组给予乙酰水杨酸(15mg/kg)、氯吡格雷(11mg/kg)、替格瑞洛(27mg/kg)和普拉格雷(1.5mg/kg)灌胃。在 MI 后 7 天,通过超声心动图和 Masson 三色染色分别评估心功能和心肌纤维化。通过组织切片进行组织病理学检查,以评估炎症细胞浸润程度。通过测量凝血酶诱导的血小板聚集来监测血小板抑制作用。
与后处理组和对照组相比,预处理组的左心室射血分数和短轴缩短率明显提高(p<0.01)。与后处理组和对照组相比,预处理组的心肌纤维化明显减少(p<0.01)。与对照组相比,预处理组的炎症细胞浸润明显减少(p<0.05)。抗血小板药物显著抑制凝血酶诱导的血小板聚集,但与 H2O2 接触后聚集增加。
在没有再灌注治疗的情况下,AMI 后抗血小板药物预处理可成功改善心功能,减少心肌纤维化和炎症细胞浸润,并抑制氧化应激诱导的血小板聚集。